P53 and Ki67 biomarkers as prognostic factors of non small cell lung carcinoma

Acta Medica Iranica

Volumn 43, Issue 2, 2005, Pages 127-130

  Saber, S ^a   Salehian, P ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ki67 antigen; Non small cell lung carcinoma; P53 protein

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PROGNOSIS; PROTO ONCOGENE; RISK FACTOR; SAMPLING; TUMOR SUPPRESSOR GENE;

EID: 26244452743     PISSN: 00446025     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991 Jul 5; 253(5015):49-53.
2. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998 Dec; 4(12):3017-3024.
3. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med. 2000 Apr; 161(4 Pt 1):1355-1367.
4. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001 Feb; 10(2):83-87.
5. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb; 50(1):7-33.
6. Brandt-Rauf PW, Pincus MR. Molecular markers of carcinogenesis. Pharmacol Ther. 1998 Feb; 77(2):135-148.
7. Esposito V, Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F, Caputi M, Giordano A. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol. 1997 Feb; 28(2):233-237.
8. Segawa Y, Kageyama M, Suzuki S, Jinno K, Takigawa N, Fujimoto N, Hotta K, Eguchi K. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study. Br J Cancer. 1998 Sep; 78(5):667-672.
9. Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000 Nov 30;343(22):1627-1633.
10. Hughes JH, Cohen MB. Nuclear matrix proteins and their potential applications to diagnostic pathology. Am J Clin Pathol. 1999 Feb; 111(2):267-274.
11. Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 2002 Jan; 9(1):28-36.
12. Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J, Meyn RE. p53 gene replacement for cancer-interactions with DNA damaging agents. Acta Oncol. 2001; 40(6):739-744.
13. Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J, Fujiwara T, Meyn RE Jr. Gene therapy approaches for the management of non-small cell lung cancer. Semin Oncol 2001 Aug; 28(4 Suppl 14):50-56.
14. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997 Jan; 150(1):1-13.
15. Soomro IN, Holmes J, Whimster WF. Predicting prognosis in lung cancer: use of proliferation marker, Ki67 monoclonal antibody. J Pak Med Assoc. 1998 Mar; 48(3):66-69.
16. Theile A, Muller KM. [Proliferation kinetics of bronchioloalveolar tumorlets]. Pathologe. 1996 Mar; 17(2):163-170.
17. +" software: version 1.3 (1998); application and help note.
18. Shiba M, Kohno H, Kakizawa K, Iizasa T, Otsuji M, Saitoh Y, Hiroshima K, Ohwada H, Fujisawa T. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer. 2000 Oct 1; 89(7):1457-1465.
19. Lan Q, Feng Z, Tian D, He X, Rothman N, Tian L, Lu X, Terry MB, Mumford JL. p53 gene expression in relation to indoor exposure to unvented coal smoke in Xuan Wei, China. J Occup Environ Med. 2001 Mar;43(3):226-230.
20. Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, Sidransky D. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res. 2000 Jun 15; 60(12):3155-3159.
21. Leopardi G, Serafini G, Simoncelli C, Ludovini V, Pistola L, Altissimi G. [Ki67 and P53 in laryngeal epithelial lesions: correlations with risk factors]. Acta Otorhinolaryngol Ital. 2001 Aug; 21(4):243-247.
22. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001 Aug 2; 20(34):4621-4628.
23. Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem. 2000 Aug; 102(3):323-338.
24. Franciosi V, Naldi N, Carbognani P, Bozzetti C, Guazzi A, Nizzoli R, Rusca M, Cocconi G. Biological characterization of non-small cell lung cancer with fine needle aspiration. Clinica Chirurgica Toracica Universita Parma Italy 1988.